ArticleMedComm2024

Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer.

Yihua Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.